Glaxo Wellcome Inc.

Zogenix International Limited

Stealth Biotherapeutics Inc.

Other

Smithkline Beecham Corporation

Trimeris, Inc.

Marc W Andersen

Derek John Londesbrough

David John Cowan

Robert Carl Andrews

Michael Howard Rabinowitz

Michael David Gaul

Susan Mary Daluge

D Travis Wilson

David Lee Musso

Brian L Bray

David Norman Deaton

Dulce Garrido Bubacz

Myung-Chol Kang

Paul Erickson Friedrich

Robert William Wiethe

Joseph Howing Chan

Daryl Lynn McDougald

Jennifer Badiang Stanford

Michael Luzzio

Leroy B Townsend

John Charles Drach

Scott M Duncan

Brian Edward Marron

Stanley Dawes Chamberlain

Scott Howard Dickerson

Jan Oudenes

David Harold Drewry

Mark J Bamberger

George Andrew Freeman

Frank Leslie Boyd, Jr

Brian Blakey

Elizabeth Mead

Derek Londesbrough

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

Aromatic-cationic peptides and uses of same

Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and

Fenfluramine compositions and methods of preparing the same

Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified amino acid residues, which increases the efficiency of the synthetic process and the purity of the peptide product generated.

N-carboxyanhydride-based-scale synthesis of elamipretide

Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.

Methods for treatment of atherosclerosis

The present invention relates, first, to methods for the synthesis of peptides referred to as T-1249 and T-1249-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide fragments to yield the peptide of interest. The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the peptides on interest (e.g., T-1249). The present invention still further relates to groups of such peptide intermediate fragments which can be utilized together to produce full-length T-1249 and T-1249-like peptides.

Methods and compositions for peptide synthesis

Methods and composition for peptide synthesis

Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.

Growing community of inventors

Raleigh, NC, United States of America

Marc W Andersen